The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4 billion ($17.2 billion), on strong US demand for rapid COVID-19 antigen tests, as well as the performances of ...

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...

The UAB Department of OB/GYN has a rich history in perinatal research. A list of samples stores as part of the research biorepository is outlined below. Study (PI) Specimen Type Collected (sample ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing ...